
Recent developments with Halozyme Therapeutics Inc (HALO) have led to the company’s beta value being reach 1.19 cents.
Halozyme Therapeutics Inc (NASDAQ: HALO) kicked off on Tuesday, down -4.19% from the previous trading day, before settling in for the closing price of $55.64.